Dermira Inc. (NASDAQ:DERM) CEO Thomas G. Wiggans sold 11,000 shares of the business’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of $34.60, for a total transaction of $380,600.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Shares of Dermira Inc. (NASDAQ:DERM) opened at 35.04 on Thursday. Dermira Inc. has a 1-year low of $17.42 and a 1-year high of $36.16. The stock has a 50 day moving average price of $33.12 and a 200 day moving average price of $29.46. The stock’s market capitalization is $1.24 billion.
Dermira (NASDAQ:DERM) last released its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.86) by $0.03. Equities research analysts anticipate that Dermira Inc. will post ($3.39) EPS for the current year.
Institutional investors have recently added to or reduced their stakes in the stock. TimesSquare Capital Management LLC increased its position in Dermira by 79.3% in the second quarter. TimesSquare Capital Management LLC now owns 2,491,526 shares of the biopharmaceutical company’s stock worth $72,877,000 after buying an additional 1,101,645 shares in the last quarter. FMR LLC increased its position in Dermira by 29.3% in the second quarter. FMR LLC now owns 4,063,136 shares of the biopharmaceutical company’s stock worth $118,847,000 after buying an additional 921,800 shares in the last quarter. Jennison Associates LLC increased its position in Dermira by 52.0% in the second quarter. Jennison Associates LLC now owns 2,514,166 shares of the biopharmaceutical company’s stock worth $73,539,000 after buying an additional 860,597 shares in the last quarter. Loomis Sayles & Co. L P acquired a new position in Dermira during the second quarter worth about $10,678,000. Finally, Vanguard Group Inc. increased its position in Dermira by 47.9% in the second quarter. Vanguard Group Inc. now owns 941,164 shares of the biopharmaceutical company’s stock worth $27,529,000 after buying an additional 304,750 shares in the last quarter. Hedge funds and other institutional investors own 82.46% of the company’s stock.
A number of equities research analysts have weighed in on the stock. Leerink Swann reiterated a “buy” rating on shares of Dermira in a research note on Wednesday. Needham & Company LLC reiterated a “positive” rating and set a $46.00 target price on shares of Dermira in a research note on Monday. Finally, Zacks Investment Research upgraded shares of Dermira from a “sell” rating to a “hold” rating in a research note on Tuesday, August 2nd. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $41.00.
Dermira, Inc is a biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies for dermatologic diseases. The Company’s portfolio includes three late-stage product candidates that target unmet needs and market opportunities, such as Cimzia (certolizumab pegol), DRM04 and DRM01.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.